Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
企業コードAVDL
会社名Avadel Pharmaceuticals PLC
上場日Jan 16, 1952
最高経営責任者「CEO」Mr. Gregory J. (Greg) Divis, Jr.
従業員数188
証券種類Ordinary Share
決算期末Jan 16
本社所在地Block 10-1 Blanchardstown Corporate Park
都市DUBLIN
証券取引所NASDAQ Global Market Consolidated
国Ireland
郵便番号15
電話番号35319015201
ウェブサイトhttps://www.avadel.com/
企業コードAVDL
上場日Jan 16, 1952
最高経営責任者「CEO」Mr. Gregory J. (Greg) Divis, Jr.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし